Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 19.73 -0.58 (2.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.31 | 52 Week High | $42.49 | |||
| Open | $20.22 | 52 Week Low | $16.64 | |||
| Day High | $20.25 | P/E | N/A | |||
| Day Low | $19.58 | EPS | $-0.42 | |||
| Volume | 1,066,085 | |||||
